Delving into the Latest Updates on Sanjin Group Hunan Sanjin Pharmaceutical Co. Ltd. with Synapse

Overview

Tags

Infectious Diseases

Mouth and Tooth Diseases

Respiratory Diseases

Herbal medicine

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

No Data

Disease Domain	Count

Infectious Diseases	3

Top 5 Drug Type	Count

Herbal medicine	3

本试验旨在研究单次空腹和餐后口服三金集团湖南三金制药有限责任公司研制、生产的拉莫三嗪片（50 mg）的药代动力学特征；以GlaxoSmithKline Pharmaceuticals S.A.（持证商： The Wellcome Foundation Limited）生产的拉莫三嗪片（利必通®，50 mg）为参比制剂，比较两制剂中药动学参数Cmax、AUC0-t、AUC0-72，评价两制剂的人体生物等效性。

[Translation]

This study aimed to investigate the pharmacokinetic characteristics of lamotrigine tablets (50 mg) developed and produced by Hunan Sanjin Pharmaceutical Co., Ltd. of Sanjin Group after single fasting and postprandial oral administration; Lamotrigine tablets (Lamictal®, 50 mg) produced by GlaxoSmithKline Pharmaceuticals S.A. (licensee: The Wellcome Foundation Limited) were used as reference preparations, and the pharmacokinetic parameters Cmax, AUC0-t, and AUC0-72 of the two preparations were compared to evaluate the bioequivalence of the two preparations in humans.

Start Date04 Jan 2019

Sponsor / Collaborator

Sanjin Group Hunan Sanjin Pharmaceutical Co. Ltd.

100 Clinical Results associated with Sanjin Group Hunan Sanjin Pharmaceutical Co. Ltd.

Login to view more data

0 Patents (Medical) associated with Sanjin Group Hunan Sanjin Pharmaceutical Co. Ltd.

Login to view more data

1

Literatures (Medical) associated with Sanjin Group Hunan Sanjin Pharmaceutical Co. Ltd.

BMC Complementary Medicine and Therapies

Artichoke (Cynara scolymus L.) water extract alleviates palmitate-induced insulin resistance in HepG2 hepatocytes via the activation of IRS1/PI3K/AKT/FoxO1 and GSK-3β signaling pathway

Article

Author: Xiao, Bing ; Chen, Jun ; Mo, Ping ; Deng, Aihua ; Huang, Kerui ; Xie, Peng ; Wang, Yun ; Chen, Kaiyi ; Liu, Fengying

AbstractBackgroundArtichoke (Cynara scolymus L.) is a typical element of a traditional Mediterranean diet and has potential health advantages for insulin resistance (IR) and type 2 diabetes mellitus (T2DM). This study aims to evaluate the effect and underlying mechanism of artichoke water extract (AWE) on palmitate (PA)-induced IR in human hepatocellular carcinoma (HepG2) cells.MethodsThe effect of AWE on cell viability was determined using CCK8 assay. Cellular glucose uptake, glucose consumption, glucose production, and glycogen content were assessed after AWE treatment. The gene expression and protein levels were examined by real-time polymerase chain reaction (qRT-PCR) and western blotting.ResultsThe results showed that AWE dose-dependently increased cell viability in IR HepG2 cells (P < 0.01). AWE treatment significantly promoted glucose uptake and consumption, decreased glucose production, and increased the cellular glycogen content in IR HepG2 cells (P < 0.01). Mechanistically, AWE elevated the phosphorylation and total protein levels of major insulin signaling molecules in IR HepG2 cells, which resulted in a decrease in the expression of phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase) and the inhibition of glycogen synthase (GS) phosphorylation in IR HepG2 cells. Furthermore, the protective effect of AWE on IR HepG2 cells might be ascribed to the inhibition of the endoplasmic reticulum (ER) stress.ConclusionWe conclude that AWE may improve glucose metabolism by regulating IRS1/PI3K/AKT/FoxO1 and GSK-3β signaling associated with the inhibition of ER stress in IR HepG2 cells induced by PA.

100 Deals associated with Sanjin Group Hunan Sanjin Pharmaceutical Co. Ltd.

Login to view more data

100 Translational Medicine associated with Sanjin Group Hunan Sanjin Pharmaceutical Co. Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 05 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Approved

3

Login to view more data